How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

IM

NASDAQ:IMVT
Get a brief AI stock analysisSaves ~ 15 minutes of your time

IM

Immunovant IncNASDAQ IMVT Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is IMVT undervalued compared to its fair value?

The fair value of IMVT stock is hidden USD. Relative to the market price of 27.97 USD Immunovant Inc is hidden.

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 124 full-time employees. The company went IPO on 2019-05-14. The firm is focus...[More about valuation]

Immunovant Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

4.153 $B

Price:

27.97 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.356

FINANCIALS

Immunovant financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.062 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.051 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.71 B
0.68 B

Financial Position Analysis

Assets

0.71 B
Current Assets
0.71 B
Total non-current assets
0.0007 B

Total current liabilities
0.032 B
Total non-current liabilities

Cash Flow Statement

-0.047 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.047 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Immunovant fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is IMVT attractive for investment based on fundamental analysis?

IMVT stock rating is hidden. Immunovant is a hidden by Eyestock methodology.

Get IMVT Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

IMVT analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for IMVT to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Immunovant Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Immunovant Inc dividends

IMVT dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About IMVT stock

About the company Immunovant Inc

Market cap $B

4.153

Dividend yield

Shares outstanding

130.245 B

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 124 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. The firm's product candidate, batoclimab, is a fully human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for Myasthenia Gravis (MG), Thyroid Eye Disease (TED) and Warm Autoimmune Hemolytic Anemia (WAIHA). The firm is conducting a phase I drug-drug interaction (DDI) study in healthy volunteers to characterize the pharmacokinetic (PK) profile of atorvastatin with and without the coadministration of batoclimab.

IMVT profile

  • Ticker

    IMVT

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    14 May 2019

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    124

  • City

    New York City

  • Address

    320 West 37Th Street

  • Cusip

    45258J102